ERBB2 and non-small cell lung carcinoma: The combination therapy, particularly, showed enhanced effectiveness with an ORR of 47.6% and a mPFS of 8.1 months, underscoring the significant clinical benefits RC48 may offer to patients with HER2-altered NSCLC.